Home > Pulmonology > ATS 2019 > Pulmonary Vascular Disease and Interstitial Lung Disease > Long-Term Safety and Efficacy of Recombinant Human Pentraxin-2 in Patients with Idiopathic Pulmonary Fibrosis

Long-Term Safety and Efficacy of Recombinant Human Pentraxin-2 in Patients with Idiopathic Pulmonary Fibrosis

Presented By
Prof. Ganesh Raghu’s, University of Washington, Seattle, USA
Conference
ATS 2019
Trial
PRM-151-202

Patients who completed the initial 28-week double-blind period (n=116) of the PRM-151-202 trial were eligible to participate in the open-label extension study (n=111). The 76-week results of this open-label extension study were published in the Lancet Respiratory Medicine during Prof. Ganesh Raghu’s (University of Washington, Seattle, USA) presentation. Long-term treatment with PRM-151 was well tolerated and the effects on percentage of predicted FVC and 6-min walking distance were persistent on continuation and positive in patients who crossed over from placebo [1, 2].

Recombinant human pentraxin-2 (PRM-151), also known as serum amyloid P, has been shown to reduce fibrosis in preclinical and early trial settings. Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease with a median survival of 3-5 years after diagnosis. Currently available anti-fibrotic medical interventions retard but d...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on